FindTrial
Sign In

Combined oral iron chelation in thalassemia

Efficacy and safety of combined oral chelation with deferiprone and deferasirox on iron overload in children with transfusion dependent thalassemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/012134
Enrollment
20
Registered
2018-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Thalassemia Health Condition 2: D569- Thalassemia, unspecified

Interventions

None listed

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children of age 2-18 years with thalassemia and serum ferritin >= 1500ng/ml

Exclusion criteria

Exclusion criteria: Children with 1. Serum creatinine more than two times the upper limit for age 2. Serum aspartate amino transferase and alanine amino transferase more than five times the upper limit for age 3. Children with absolute neutrophil count less than 1500/mm3 and platelets less than 1 lakh/mm3 4. Significant proteinuria defined by protein creatinine ratio more than 0.5 5. Cardiac failure secondary to myocardial iron toxicity 6. Previous history of allergic reaction to deferiprone or deferasirox

Design outcomes

Primary

MeasureTime frame
Change in serum ferritin levelsTimepoint: 1 year—

Secondary

MeasureTime frame
1) Change in cardiac iron concentration quantified by MRI 2) Change in liver iron concentration quantified by MRITimepoint: 1 year—

Countries

India

Contacts

Public ContactDivakar Jose

JIPMER

dillikumar14@gmail.com9566028886

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026